The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review
Abstract
Hastono Ridwansyah, Achmad Hussein S. Kartamihardja, Muhammad Hasan Bashari, Bethy
The treatment of B-cell non-Hodgkin lymphoma (NHL) still has the problems, such as a high rate of relapse and refractory case. The use of radioimmunotherapy (RIT) appears to be a treatment modality expected to resolve the problem. However, RIT remains underused in a clinical practice setting for B-cell NHL treatment. This study was conducted to find out the treatment potency of RIT in patients with B-cell lymphoma, particularly in indolent or aggressive NHL patients. This literature review was conducted in a systematic review from many kinds of literature published from 2010 to 2020 using keyword combinations, including “radioimmunotherapy”, “aggressive lymphoma”, “diffuse large B-cell lymphoma”, “indolent lymphoma”, and “follicular lymphoma”. Those keywords were entered in the advanced search of Cochrane Library and Pubmed. There were 84 articles collected based on those keywords and among them, only 30 articles containing antibody anti-CD20 fulfilled the inclusion and exclusion criteria. Articles reporting the efficacy and safety of RIT as the first-line and consolidation of aggressive and indolent lymphoma were 5 and 11 articles respectively, and as relapsed/refractory treatment were 9 and 5 articles, respectively. Radiopharmaceuticals used were 90Y-ibritumomab-tiuxetan, 131I-tositumomab, and 131I-rituximab. The conclusion is that RIT, mainly 90Y-ibritumomab tiuxetan, has shown favorable and safe clinical outcomes for indolent and aggressive B-cell NHL, and it has a greater opportunity of being used as B-cell NHL treatment to improve ORR and overall patient survival in a clinical practice setting.
| How to Cite this Article |
| Pubmed Style Ridwansyah H, Kartamihardja AHS, Bashari MH, Hernowo BS. The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review. SRP. 2021; 12(1): 935-947. doi:10.31838/srp.2021.1.131 Web Style Ridwansyah H, Kartamihardja AHS, Bashari MH, Hernowo BS. The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review. http://www.sysrevpharm.org/?mno=45560 [Access: March 30, 2021]. doi:10.31838/srp.2021.1.131 AMA (American Medical Association) Style Ridwansyah H, Kartamihardja AHS, Bashari MH, Hernowo BS. The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review. SRP. 2021; 12(1): 935-947. doi:10.31838/srp.2021.1.131 Vancouver/ICMJE Style Ridwansyah H, Kartamihardja AHS, Bashari MH, Hernowo BS. The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review. SRP. (2021), [cited March 30, 2021]; 12(1): 935-947. doi:10.31838/srp.2021.1.131 Harvard Style Ridwansyah, H., Kartamihardja, . A. H. S., Bashari, . M. H. & Hernowo, . B. S. (2021) The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review. SRP, 12 (1), 935-947. doi:10.31838/srp.2021.1.131 Turabian Style Ridwansyah, Hastono, Achmad Hussein S. Kartamihardja, Muhammad Hasan Bashari, and Bethy Suryawathy Hernowo. 2021. The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review. Systematic Reviews in Pharmacy, 12 (1), 935-947. doi:10.31838/srp.2021.1.131 Chicago Style Ridwansyah, Hastono, Achmad Hussein S. Kartamihardja, Muhammad Hasan Bashari, and Bethy Suryawathy Hernowo. "The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review." Systematic Reviews in Pharmacy 12 (2021), 935-947. doi:10.31838/srp.2021.1.131 MLA (The Modern Language Association) Style Ridwansyah, Hastono, Achmad Hussein S. Kartamihardja, Muhammad Hasan Bashari, and Bethy Suryawathy Hernowo. "The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review." Systematic Reviews in Pharmacy 12.1 (2021), 935-947. Print. doi:10.31838/srp.2021.1.131 APA (American Psychological Association) Style Ridwansyah, H., Kartamihardja, . A. H. S., Bashari, . M. H. & Hernowo, . B. S. (2021) The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review. Systematic Reviews in Pharmacy, 12 (1), 935-947. doi:10.31838/srp.2021.1.131 |
Abstract
PDF
How to cite this article
Related Records